Does TAFASITAMAB Cause Febrile neutropenia? 64 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 64 reports of Febrile neutropenia have been filed in association with TAFASITAMAB (MONJUVI). This represents 4.6% of all adverse event reports for TAFASITAMAB.
64
Reports of Febrile neutropenia with TAFASITAMAB
4.6%
of all TAFASITAMAB reports
7
Deaths
55
Hospitalizations
How Dangerous Is Febrile neutropenia From TAFASITAMAB?
Of the 64 reports, 7 (10.9%) resulted in death, 55 (85.9%) required hospitalization, and 22 (34.4%) were considered life-threatening.
Is Febrile neutropenia Listed in the Official Label?
Yes, Febrile neutropenia is listed as a known adverse reaction in the official FDA drug label for TAFASITAMAB.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Drug ineffective (62)
Thrombocytopenia (60)
What Other Drugs Cause Febrile neutropenia?
CYCLOPHOSPHAMIDE (11,318)
DOXORUBICIN (8,844)
VINCRISTINE (8,676)
RITUXIMAB (6,382)
CYTARABINE (6,142)
METHOTREXATE (6,091)
ETOPOSIDE (5,966)
CARBOPLATIN (4,888)
DEXAMETHASONE (4,382)
PREDNISONE (3,956)
Which TAFASITAMAB Alternatives Have Lower Febrile neutropenia Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR